DK3194403T3 - PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS - Google Patents
PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS Download PDFInfo
- Publication number
- DK3194403T3 DK3194403T3 DK15779059.3T DK15779059T DK3194403T3 DK 3194403 T3 DK3194403 T3 DK 3194403T3 DK 15779059 T DK15779059 T DK 15779059T DK 3194403 T3 DK3194403 T3 DK 3194403T3
- Authority
- DK
- Denmark
- Prior art keywords
- mmol
- formula
- chemical entity
- difluoro
- ethyl
- Prior art date
Links
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title description 6
- 108010054200 NR2B NMDA receptor Proteins 0.000 title description 2
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 231
- 150000001875 compounds Chemical class 0.000 claims description 208
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 180
- 150000005829 chemical entities Chemical class 0.000 claims description 156
- -1 -CHs Chemical group 0.000 claims description 133
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 122
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 115
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 81
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 64
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 59
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims description 55
- 125000001153 fluoro group Chemical group F* 0.000 claims description 47
- 208000035475 disorder Diseases 0.000 claims description 37
- 238000011282 treatment Methods 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 22
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 22
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- 208000002193 Pain Diseases 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 230000036407 pain Effects 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 7
- 208000011117 substance-related disease Diseases 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical group 0.000 claims description 6
- 201000009032 substance abuse Diseases 0.000 claims description 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 5
- 231100000736 substance abuse Toxicity 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000016285 Movement disease Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims 4
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 102000034527 Retinoid X Receptors Human genes 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 337
- 239000000203 mixture Substances 0.000 description 230
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 189
- 239000000243 solution Substances 0.000 description 157
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 152
- 235000019439 ethyl acetate Nutrition 0.000 description 141
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 132
- 238000005160 1H NMR spectroscopy Methods 0.000 description 129
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 117
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 117
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 117
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 104
- 238000003756 stirring Methods 0.000 description 100
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 93
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 88
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 84
- 238000004440 column chromatography Methods 0.000 description 81
- 239000000741 silica gel Substances 0.000 description 81
- 229910002027 silica gel Inorganic materials 0.000 description 81
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 80
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 74
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 74
- 239000007787 solid Substances 0.000 description 72
- 239000012267 brine Substances 0.000 description 71
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 71
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 68
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 65
- 239000012141 concentrate Substances 0.000 description 65
- 235000008504 concentrate Nutrition 0.000 description 65
- 239000000843 powder Substances 0.000 description 64
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 56
- 229940093499 ethyl acetate Drugs 0.000 description 55
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 54
- 239000012074 organic phase Substances 0.000 description 52
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 48
- 239000000725 suspension Substances 0.000 description 46
- 239000003814 drug Substances 0.000 description 45
- 239000011541 reaction mixture Substances 0.000 description 43
- 235000002639 sodium chloride Nutrition 0.000 description 39
- 230000000694 effects Effects 0.000 description 38
- 125000000217 alkyl group Chemical group 0.000 description 35
- 206010015037 epilepsy Diseases 0.000 description 35
- 239000000543 intermediate Substances 0.000 description 33
- 238000000034 method Methods 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
- 229940079593 drug Drugs 0.000 description 31
- 206010010904 Convulsion Diseases 0.000 description 30
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 29
- 239000005457 ice water Substances 0.000 description 29
- 239000012230 colorless oil Substances 0.000 description 27
- 238000001816 cooling Methods 0.000 description 26
- 235000019441 ethanol Nutrition 0.000 description 26
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 24
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 239000000706 filtrate Substances 0.000 description 22
- 239000005557 antagonist Substances 0.000 description 21
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000012279 sodium borohydride Substances 0.000 description 19
- 229910000033 sodium borohydride Inorganic materials 0.000 description 19
- IRSJDVYTJUCXRV-UHFFFAOYSA-N ethyl 2-bromo-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Br IRSJDVYTJUCXRV-UHFFFAOYSA-N 0.000 description 18
- 239000010410 layer Substances 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- 125000003545 alkoxy group Chemical group 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- 125000005843 halogen group Chemical group 0.000 description 16
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- 239000010949 copper Substances 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- 239000003480 eluent Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 229940124597 therapeutic agent Drugs 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 208000014094 Dystonic disease Diseases 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- MAAHZLQUTFEEDN-UHFFFAOYSA-N N1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1 Chemical compound N1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1 MAAHZLQUTFEEDN-UHFFFAOYSA-N 0.000 description 11
- 208000010118 dystonia Diseases 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 210000003169 central nervous system Anatomy 0.000 description 10
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 10
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- 206010021750 Infantile Spasms Diseases 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000935 antidepressant agent Substances 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000000144 pharmacologic effect Effects 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 8
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 8
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 201000006791 West syndrome Diseases 0.000 description 8
- 238000005804 alkylation reaction Methods 0.000 description 8
- 239000001961 anticonvulsive agent Substances 0.000 description 8
- 229940005513 antidepressants Drugs 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 208000015114 central nervous system disease Diseases 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- UVECLJDRPFNRRQ-UHFFFAOYSA-N ethyl trifluoromethanesulfonate Chemical compound CCOS(=O)(=O)C(F)(F)F UVECLJDRPFNRRQ-UHFFFAOYSA-N 0.000 description 8
- 229960003299 ketamine Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 230000001037 epileptic effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229930195712 glutamate Natural products 0.000 description 7
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 6
- 206010008748 Chorea Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 6
- 102000034570 NR1 subfamily Human genes 0.000 description 6
- 108020001305 NR1 subfamily Proteins 0.000 description 6
- 102000038100 NR2 subfamily Human genes 0.000 description 6
- 108020002076 NR2 subfamily Proteins 0.000 description 6
- 208000018737 Parkinson disease Diseases 0.000 description 6
- 206010061334 Partial seizures Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 230000001430 anti-depressive effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- QEMSVZNTSXPFJA-HNAYVOBHSA-N 1-[(1s,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol Chemical compound C1([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=CC=C(O)C=C1 QEMSVZNTSXPFJA-HNAYVOBHSA-N 0.000 description 5
- 208000014644 Brain disease Diseases 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- 208000032274 Encephalopathy Diseases 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000002033 Myoclonus Diseases 0.000 description 5
- 206010034010 Parkinsonism Diseases 0.000 description 5
- 208000037158 Partial Epilepsies Diseases 0.000 description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 230000009102 absorption Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 208000012601 choreatic disease Diseases 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 5
- 235000019797 dipotassium phosphate Nutrition 0.000 description 5
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 238000002651 drug therapy Methods 0.000 description 5
- 201000007186 focal epilepsy Diseases 0.000 description 5
- 229960003878 haloperidol Drugs 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 238000007125 Buchwald synthesis reaction Methods 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 208000012661 Dyskinesia Diseases 0.000 description 4
- KXZSHSUBGGJHMF-UHFFFAOYSA-N FC(CN1CCC(CC1)N(C=1C2=C(N=CN=1)NC=C2)C)(C1=NC=C(C=C1)C)F Chemical compound FC(CN1CCC(CC1)N(C=1C2=C(N=CN=1)NC=C2)C)(C1=NC=C(C=C1)C)F KXZSHSUBGGJHMF-UHFFFAOYSA-N 0.000 description 4
- ZDFURGJEKXLSIA-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=CC=C(C=C1)C(F)(F)F)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=CC=C(C=C1)C(F)(F)F)F ZDFURGJEKXLSIA-UHFFFAOYSA-N 0.000 description 4
- IRQVJAHFRCOUEM-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=C(C=C1)OC(F)(F)F)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=C(C=C1)OC(F)(F)F)F IRQVJAHFRCOUEM-UHFFFAOYSA-N 0.000 description 4
- PPDYAKFPCMNKDG-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=C(C=C1F)C)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=C(C=C1F)C)F PPDYAKFPCMNKDG-UHFFFAOYSA-N 0.000 description 4
- OLLWXMDGFDGOBR-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=C(N=C1)C)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=C(N=C1)C)F OLLWXMDGFDGOBR-UHFFFAOYSA-N 0.000 description 4
- WUWHHPDUDHFRLP-UHFFFAOYSA-N FC(OC=1C=CC(=NC=1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(F)F)F Chemical compound FC(OC=1C=CC(=NC=1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(F)F)F WUWHHPDUDHFRLP-UHFFFAOYSA-N 0.000 description 4
- 208000035899 Infantile spasms syndrome Diseases 0.000 description 4
- 102000004310 Ion Channels Human genes 0.000 description 4
- 108090000862 Ion Channels Proteins 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- AVJOGSFGYMPSTQ-UHFFFAOYSA-N [2,2-difluoro-2-(5-methylpyridin-2-yl)ethyl] trifluoromethanesulfonate Chemical compound FC(S(=O)(=O)OCC(C1=NC=C(C=C1)C)(F)F)(F)F AVJOGSFGYMPSTQ-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 238000012048 forced swim test Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 239000000346 nonvolatile oil Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 150000004684 trihydrates Chemical class 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
- MLDZNKPELBMONG-UHFFFAOYSA-N 1-(difluoromethyl)-4-iodobenzene Chemical compound FC(F)C1=CC=C(I)C=C1 MLDZNKPELBMONG-UHFFFAOYSA-N 0.000 description 3
- FEAQCBNLSBWYSC-UHFFFAOYSA-N 1-[2,2-difluoro-2-(5-methylpyridin-2-yl)ethyl]piperidin-4-amine Chemical compound FC(CN1CCC(CC1)N)(C1=NC=C(C=C1)C)F FEAQCBNLSBWYSC-UHFFFAOYSA-N 0.000 description 3
- MWOOAEMPWQHEBI-UHFFFAOYSA-N 1-[2,2-difluoro-2-[5-(trifluoromethyl)pyridin-2-yl]ethyl]piperidin-4-amine Chemical compound FC(CN1CCC(CC1)N)(C1=NC=C(C=C1)C(F)(F)F)F MWOOAEMPWQHEBI-UHFFFAOYSA-N 0.000 description 3
- YCGOQVUUXGWMFP-UHFFFAOYSA-N 1-[2-(5-chloro-3-fluoropyridin-2-yl)-2,2-difluoroethyl]piperidin-4-amine Chemical compound ClC=1C=C(C(=NC=1)C(CN1CCC(CC1)N)(F)F)F YCGOQVUUXGWMFP-UHFFFAOYSA-N 0.000 description 3
- HLQKJOGUNGRESK-UHFFFAOYSA-N 2,2-difluoro-2-(3-fluoro-5-methylpyridin-2-yl)ethanol Chemical compound FC(CO)(C1=NC=C(C=C1F)C)F HLQKJOGUNGRESK-UHFFFAOYSA-N 0.000 description 3
- XGRLFKUJAPXWHO-UHFFFAOYSA-N 2,2-difluoro-2-(4-fluorophenyl)ethanol Chemical compound OCC(F)(F)C1=CC=C(F)C=C1 XGRLFKUJAPXWHO-UHFFFAOYSA-N 0.000 description 3
- LDUMNZLGOXQCRC-UHFFFAOYSA-N 2,2-difluoro-2-(4-methylphenyl)ethanol Chemical compound CC1=CC=C(C(F)(F)CO)C=C1 LDUMNZLGOXQCRC-UHFFFAOYSA-N 0.000 description 3
- SDJOKFADRDTWOE-UHFFFAOYSA-N 2,2-difluoro-2-(5-methylpyridin-2-yl)ethanol Chemical compound CC1=CC=C(C(F)(F)CO)N=C1 SDJOKFADRDTWOE-UHFFFAOYSA-N 0.000 description 3
- RKIPYJACLOLWHH-UHFFFAOYSA-N 2,2-difluoro-2-(6-methylpyridin-3-yl)acetic acid;hydrochloride Chemical compound Cl.CC1=CC=C(C(F)(F)C(O)=O)C=N1 RKIPYJACLOLWHH-UHFFFAOYSA-N 0.000 description 3
- WFBMRUZHFVHKEO-UHFFFAOYSA-N 2,2-difluoro-2-[5-(trifluoromethyl)pyridin-2-yl]ethanol Chemical compound FC(CO)(C1=NC=C(C=C1)C(F)(F)F)F WFBMRUZHFVHKEO-UHFFFAOYSA-N 0.000 description 3
- GIXLDZYRJQXUQB-UHFFFAOYSA-N 2,2-difluoro-2-[6-(trifluoromethyl)pyridin-3-yl]ethanol Chemical compound FC(CO)(C=1C=NC(=CC=1)C(F)(F)F)F GIXLDZYRJQXUQB-UHFFFAOYSA-N 0.000 description 3
- RTZZBUQTHNQTSR-UHFFFAOYSA-N 2,2-difluoro-2-pyridin-2-ylethanol Chemical compound OCC(F)(F)C1=CC=CC=N1 RTZZBUQTHNQTSR-UHFFFAOYSA-N 0.000 description 3
- GVFHPWOOTYUCSR-UHFFFAOYSA-N 2-(5-chloro-3-fluoropyridin-2-yl)-2,2-difluoroethanol Chemical compound ClC=1C=C(C(=NC=1)C(CO)(F)F)F GVFHPWOOTYUCSR-UHFFFAOYSA-N 0.000 description 3
- QUHDJDVFZSVUOH-UHFFFAOYSA-N 2-bromo-5-(difluoromethyl)pyridine Chemical compound FC(F)C1=CC=C(Br)N=C1 QUHDJDVFZSVUOH-UHFFFAOYSA-N 0.000 description 3
- PYDGFYYLQFJQBZ-UHFFFAOYSA-N 2-bromo-5-chloro-3-fluoropyridine Chemical compound FC1=CC(Cl)=CN=C1Br PYDGFYYLQFJQBZ-UHFFFAOYSA-N 0.000 description 3
- UODINHBLNPPDPD-UHFFFAOYSA-N 2-bromo-5-fluoropyridine Chemical compound FC1=CC=C(Br)N=C1 UODINHBLNPPDPD-UHFFFAOYSA-N 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- BTOJSYRZQZOMOK-UHFFFAOYSA-N 4-chloro-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=NC(Cl)=C2C=C1 BTOJSYRZQZOMOK-UHFFFAOYSA-N 0.000 description 3
- GBAXFWLQMVBNMV-UHFFFAOYSA-N 5-iodo-2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(I)C=N1 GBAXFWLQMVBNMV-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- JEADSSAOYVARCT-UHFFFAOYSA-N C(C)(C)(C)OC(NC1CCN(CC1)CC(C1=NC=C(N=C1)C)(F)F)=O Chemical compound C(C)(C)(C)OC(NC1CCN(CC1)CC(C1=NC=C(N=C1)C)(F)F)=O JEADSSAOYVARCT-UHFFFAOYSA-N 0.000 description 3
- IXTSOQMOJBUTIG-UHFFFAOYSA-N C(C)OC(C(F)(F)C1=NC=C(C=C1)OC(F)F)=O Chemical compound C(C)OC(C(F)(F)C1=NC=C(C=C1)OC(F)F)=O IXTSOQMOJBUTIG-UHFFFAOYSA-N 0.000 description 3
- 208000009132 Catalepsy Diseases 0.000 description 3
- PDZONIRZGMLDMR-UHFFFAOYSA-N ClC=1C=CC(=NC=1)C(CN1CCC(CC1)N)(F)F Chemical compound ClC=1C=CC(=NC=1)C(CN1CCC(CC1)N)(F)F PDZONIRZGMLDMR-UHFFFAOYSA-N 0.000 description 3
- RPTVSVKUQIGDEG-UHFFFAOYSA-N ClC=1C=CC(=NC=1)C(CO)(F)F Chemical compound ClC=1C=CC(=NC=1)C(CO)(F)F RPTVSVKUQIGDEG-UHFFFAOYSA-N 0.000 description 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- SIDXPKUOHMAISF-UHFFFAOYSA-N FC(C(=O)N1CCC(CC1)NC(OC(C)(C)C)=O)(C=1C=NC(=CC=1)C)F Chemical compound FC(C(=O)N1CCC(CC1)NC(OC(C)(C)C)=O)(C=1C=NC(=CC=1)C)F SIDXPKUOHMAISF-UHFFFAOYSA-N 0.000 description 3
- FFDBCGNKNHWVPO-UHFFFAOYSA-N FC(C(=O)OCC)(C1=NC=C(C=C1)CF)F Chemical compound FC(C(=O)OCC)(C1=NC=C(C=C1)CF)F FFDBCGNKNHWVPO-UHFFFAOYSA-N 0.000 description 3
- GJJFVONAQSGGHD-UHFFFAOYSA-N FC(C1=CC=C(C=C1)C(CN1CCC(CC1)N)(F)F)F Chemical compound FC(C1=CC=C(C=C1)C(CN1CCC(CC1)N)(F)F)F GJJFVONAQSGGHD-UHFFFAOYSA-N 0.000 description 3
- AQQNBDCGRJFHMO-UHFFFAOYSA-N FC(C1=CC=C(C=C1)C(CN1CCC(CC1)NC(OC(C)(C)C)=O)(F)F)F Chemical compound FC(C1=CC=C(C=C1)C(CN1CCC(CC1)NC(OC(C)(C)C)=O)(F)F)F AQQNBDCGRJFHMO-UHFFFAOYSA-N 0.000 description 3
- ANKBZGWFRHIKFI-UHFFFAOYSA-N FC(C1=CC=C(C=C1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(F)F)F Chemical compound FC(C1=CC=C(C=C1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(F)F)F ANKBZGWFRHIKFI-UHFFFAOYSA-N 0.000 description 3
- ZMVZJRNNOJEEFC-UHFFFAOYSA-N FC(C1=CC=C(C=C1)C(CO)(F)F)F Chemical compound FC(C1=CC=C(C=C1)C(CO)(F)F)F ZMVZJRNNOJEEFC-UHFFFAOYSA-N 0.000 description 3
- WPSJKAUCZMWWTK-UHFFFAOYSA-N FC(C=1C=CC(=NC=1)C(C(=O)OCC)(F)F)F Chemical compound FC(C=1C=CC(=NC=1)C(C(=O)OCC)(F)F)F WPSJKAUCZMWWTK-UHFFFAOYSA-N 0.000 description 3
- BYPXAXHKCRTPBH-UHFFFAOYSA-N FC(C=1C=CC(=NC=1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)(F)F)F Chemical compound FC(C=1C=CC(=NC=1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)(F)F)F BYPXAXHKCRTPBH-UHFFFAOYSA-N 0.000 description 3
- RLYSZZRBCWPAFD-UHFFFAOYSA-N FC(C=1C=CC(=NC=1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(F)F)F Chemical compound FC(C=1C=CC(=NC=1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(F)F)F RLYSZZRBCWPAFD-UHFFFAOYSA-N 0.000 description 3
- JOYALRSSDPAXDG-UHFFFAOYSA-N FC(CN1CCC(CC1)N)(C1=CC=C(C=C1)C(F)(F)F)F Chemical compound FC(CN1CCC(CC1)N)(C1=CC=C(C=C1)C(F)(F)F)F JOYALRSSDPAXDG-UHFFFAOYSA-N 0.000 description 3
- OIQOBGJMQXJNFZ-UHFFFAOYSA-N FC(CN1CCC(CC1)N)(C1=CC=C(C=C1)C)F Chemical compound FC(CN1CCC(CC1)N)(C1=CC=C(C=C1)C)F OIQOBGJMQXJNFZ-UHFFFAOYSA-N 0.000 description 3
- XHQSYOCFTGZXLT-UHFFFAOYSA-N FC(CN1CCC(CC1)N)(C1=NC=C(C=C1)F)F Chemical compound FC(CN1CCC(CC1)N)(C1=NC=C(C=C1)F)F XHQSYOCFTGZXLT-UHFFFAOYSA-N 0.000 description 3
- MKEVDVNBIAOOOU-UHFFFAOYSA-N FC(CN1CCC(CC1)N)(C1=NC=C(N=C1)C)F Chemical compound FC(CN1CCC(CC1)N)(C1=NC=C(N=C1)C)F MKEVDVNBIAOOOU-UHFFFAOYSA-N 0.000 description 3
- ZDXXOGRKHIIPBZ-UHFFFAOYSA-N FC(CN1CCC(CC1)N)(C1=NC=CC=C1)F Chemical compound FC(CN1CCC(CC1)N)(C1=NC=CC=C1)F ZDXXOGRKHIIPBZ-UHFFFAOYSA-N 0.000 description 3
- BMRASSRVOSZHEW-UHFFFAOYSA-N FC(CN1CCC(CC1)N)(C=1C=NC(=CC=1)C)F Chemical compound FC(CN1CCC(CC1)N)(C=1C=NC(=CC=1)C)F BMRASSRVOSZHEW-UHFFFAOYSA-N 0.000 description 3
- DOKAKEALJWYAHC-UHFFFAOYSA-N FC(CN1CCC(CC1)NC(OC(C)(C)C)=O)(C1=CC=C(C=C1)C)F Chemical compound FC(CN1CCC(CC1)NC(OC(C)(C)C)=O)(C1=CC=C(C=C1)C)F DOKAKEALJWYAHC-UHFFFAOYSA-N 0.000 description 3
- ZXEKTELSWGREFK-UHFFFAOYSA-N FC(CN1CCC(CC1)NC(OC(C)(C)C)=O)(C1=CC=C(C=C1)F)F Chemical compound FC(CN1CCC(CC1)NC(OC(C)(C)C)=O)(C1=CC=C(C=C1)F)F ZXEKTELSWGREFK-UHFFFAOYSA-N 0.000 description 3
- MQYKIWHNAYAPAA-UHFFFAOYSA-N FC(CN1CCC(CC1)NC(OC(C)(C)C)=O)(C1=NC=CC=C1)F Chemical compound FC(CN1CCC(CC1)NC(OC(C)(C)C)=O)(C1=NC=CC=C1)F MQYKIWHNAYAPAA-UHFFFAOYSA-N 0.000 description 3
- VSHXGUWJUWPGNX-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)(C1=NC=C(C=C1F)C(F)(F)F)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)(C1=NC=C(C=C1F)C(F)(F)F)F VSHXGUWJUWPGNX-UHFFFAOYSA-N 0.000 description 3
- ZPTGKQWXVKFGAF-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=CC=C(C=C1)F)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=CC=C(C=C1)F)F ZPTGKQWXVKFGAF-UHFFFAOYSA-N 0.000 description 3
- GSSBFJAPDUTGCR-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=C(C=C1)CF)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=C(C=C1)CF)F GSSBFJAPDUTGCR-UHFFFAOYSA-N 0.000 description 3
- XEMWYEQYFGPCEW-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=C(C=C1F)C(F)(F)F)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=C(C=C1F)C(F)(F)F)F XEMWYEQYFGPCEW-UHFFFAOYSA-N 0.000 description 3
- MAXUFZSXJOBXDK-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=CC=C1)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=CC=C1)F MAXUFZSXJOBXDK-UHFFFAOYSA-N 0.000 description 3
- WFXULSHSKBXRPA-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C=1C=NC(=CC=1)C)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C=1C=NC(=CC=1)C)F WFXULSHSKBXRPA-UHFFFAOYSA-N 0.000 description 3
- BNABAIMEIWVYFD-UHFFFAOYSA-N FC(CO)(C1=NC=C(C=C1)F)F Chemical compound FC(CO)(C1=NC=C(C=C1)F)F BNABAIMEIWVYFD-UHFFFAOYSA-N 0.000 description 3
- UUGGJYOOFGQUJY-UHFFFAOYSA-N FC(CO)(C1=NC=C(N=C1)C)F Chemical compound FC(CO)(C1=NC=C(N=C1)C)F UUGGJYOOFGQUJY-UHFFFAOYSA-N 0.000 description 3
- BJSLDFZGNNHORG-UHFFFAOYSA-N FC(S(=O)(=O)OCC(C1=CC=C(C=C1)F)(F)F)(F)F Chemical compound FC(S(=O)(=O)OCC(C1=CC=C(C=C1)F)(F)F)(F)F BJSLDFZGNNHORG-UHFFFAOYSA-N 0.000 description 3
- IYQFFAUFAKNPNG-UHFFFAOYSA-N FC(S(=O)(=O)OCC(C1=NC=C(C=C1)CF)(F)F)(F)F Chemical compound FC(S(=O)(=O)OCC(C1=NC=C(C=C1)CF)(F)F)(F)F IYQFFAUFAKNPNG-UHFFFAOYSA-N 0.000 description 3
- LBVHGFIRZBYHHW-UHFFFAOYSA-N FC(S(=O)(=O)OCC(F)(F)C1=CC=C(C=C1)C(F)F)(F)F Chemical compound FC(S(=O)(=O)OCC(F)(F)C1=CC=C(C=C1)C(F)F)(F)F LBVHGFIRZBYHHW-UHFFFAOYSA-N 0.000 description 3
- 102000018899 Glutamate Receptors Human genes 0.000 description 3
- 108010027915 Glutamate Receptors Proteins 0.000 description 3
- 206010019196 Head injury Diseases 0.000 description 3
- 101000972850 Homo sapiens Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 description 3
- 206010071082 Juvenile myoclonic epilepsy Diseases 0.000 description 3
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 3
- NTMXMRKJKVFRLP-UHFFFAOYSA-N N-[1-[2,2-difluoro-2-[5-(trifluoromethyl)pyridin-2-yl]ethyl]piperidin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=C(C=C1)C(F)(F)F)F NTMXMRKJKVFRLP-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DSBHGWITGSLZTD-UHFFFAOYSA-N S(=O)(=O)(C1=CC=C(C)C=C1)N1C=CC2=C1N=CN=C2NC1CCN(CC1)C(=O)OC(C)(C)C Chemical compound S(=O)(=O)(C1=CC=C(C)C=C1)N1C=CC2=C1N=CN=C2NC1CCN(CC1)C(=O)OC(C)(C)C DSBHGWITGSLZTD-UHFFFAOYSA-N 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 206010047853 Waxy flexibility Diseases 0.000 description 3
- QVNBMQBWVZQVGD-UHFFFAOYSA-N [2,2-difluoro-2-(3-fluoro-5-methylpyridin-2-yl)ethyl] trifluoromethanesulfonate Chemical compound FC(S(=O)(=O)OCC(C1=NC=C(C=C1F)C)(F)F)(F)F QVNBMQBWVZQVGD-UHFFFAOYSA-N 0.000 description 3
- FRTKOLMWGVBCGR-UHFFFAOYSA-N [2,2-difluoro-2-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]ethyl] trifluoromethanesulfonate Chemical compound FC(S(=O)(=O)OCC(C1=NC=C(C=C1F)C(F)(F)F)(F)F)(F)F FRTKOLMWGVBCGR-UHFFFAOYSA-N 0.000 description 3
- ILEFNUATRGDJQT-UHFFFAOYSA-N [2,2-difluoro-2-[5-(trifluoromethyl)pyridin-2-yl]ethyl] trifluoromethanesulfonate Chemical compound FC(S(=O)(=O)OCC(C1=NC=C(C=C1)C(F)(F)F)(F)F)(F)F ILEFNUATRGDJQT-UHFFFAOYSA-N 0.000 description 3
- WOVILEQEPIUCDE-UHFFFAOYSA-N [2,2-difluoro-2-[6-(trifluoromethyl)pyridin-3-yl]ethyl] trifluoromethanesulfonate Chemical compound FC(S(=O)(=O)OCC(C=1C=NC(=CC=1)C(F)(F)F)(F)F)(F)F WOVILEQEPIUCDE-UHFFFAOYSA-N 0.000 description 3
- 208000003554 absence epilepsy Diseases 0.000 description 3
- 208000028311 absence seizure Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 229940005529 antipsychotics Drugs 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- ROHULWJKQBOWNS-UHFFFAOYSA-N ethyl 2,2-difluoro-2-[6-(trifluoromethyl)pyridin-3-yl]acetate Chemical compound FC(C(=O)OCC)(C=1C=NC(=CC=1)C(F)(F)F)F ROHULWJKQBOWNS-UHFFFAOYSA-N 0.000 description 3
- VGULHXRXMXNYHN-UHFFFAOYSA-N ethyl 2-(4-chlorophenyl)-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)C1=CC=C(Cl)C=C1 VGULHXRXMXNYHN-UHFFFAOYSA-N 0.000 description 3
- ZBZHSRGJKCZRJU-UHFFFAOYSA-N ethyl 2-(5-chloro-3-fluoropyridin-2-yl)-2,2-difluoroacetate Chemical compound ClC=1C=C(C(=NC=1)C(C(=O)OCC)(F)F)F ZBZHSRGJKCZRJU-UHFFFAOYSA-N 0.000 description 3
- OWBJAYNOEOGWTJ-UHFFFAOYSA-N ethyl 2-(5-chloropyridin-2-yl)-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)C1=CC=C(Cl)C=N1 OWBJAYNOEOGWTJ-UHFFFAOYSA-N 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 208000034287 idiopathic generalized susceptibility to 7 epilepsy Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000003176 neuroleptic agent Substances 0.000 description 3
- 230000000701 neuroleptic effect Effects 0.000 description 3
- 229960002715 nicotine Drugs 0.000 description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- YVBNIOQHQVMNMH-UHFFFAOYSA-N tert-butyl N-[1-[2-(5-chloro-3-fluoropyridin-2-yl)-2,2-difluoroethyl]piperidin-4-yl]carbamate Chemical compound ClC=1C=C(C(=NC=1)C(CN1CCC(CC1)NC(OC(C)(C)C)=O)(F)F)F YVBNIOQHQVMNMH-UHFFFAOYSA-N 0.000 description 3
- VHYXAWLOJGIJPC-UHFFFAOYSA-N tert-butyl n-(piperidin-4-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCNCC1 VHYXAWLOJGIJPC-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- RVBGGTKVWRZUJX-UHFFFAOYSA-N 1-[2-(4-chlorophenyl)-2,2-difluoroethyl]piperidin-4-amine Chemical compound C1CC(N)CCN1CC(F)(F)C1=CC=C(Cl)C=C1 RVBGGTKVWRZUJX-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WXHYRKUXUVQSIA-UHFFFAOYSA-N 2,2-difluoro-2-[4-(trifluoromethyl)phenyl]ethanol Chemical compound FC(CO)(C1=CC=C(C=C1)C(F)(F)F)F WXHYRKUXUVQSIA-UHFFFAOYSA-N 0.000 description 2
- KNXSIHRPENLRSE-UHFFFAOYSA-N 2-(4-chlorophenyl)-2,2-difluoroethanol Chemical compound OCC(F)(F)C1=CC=C(Cl)C=C1 KNXSIHRPENLRSE-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- GSKMWMFOQQBVMI-UHFFFAOYSA-N 2-bromo-5-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Br)N=C1 GSKMWMFOQQBVMI-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 230000035502 ADME Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010052075 Acquired epileptic aphasia Diseases 0.000 description 2
- 206010001541 Akinesia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ULBYBPUXHAXEHF-UHFFFAOYSA-N C(C)(C)(C)OC(NC1CCN(CC1)CC(F)(F)C1=CC=C(C=C1)Cl)=O Chemical compound C(C)(C)(C)OC(NC1CCN(CC1)CC(F)(F)C1=CC=C(C=C1)Cl)=O ULBYBPUXHAXEHF-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 201000001913 Childhood absence epilepsy Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- NOUXJBRIPLEKKH-UHFFFAOYSA-N ClC=1C=C(C(=NC=1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(F)F)F Chemical compound ClC=1C=C(C(=NC=1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(F)F)F NOUXJBRIPLEKKH-UHFFFAOYSA-N 0.000 description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 2
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 2
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 2
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 2
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 2
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- HIAGFGLYKBPSCG-UHFFFAOYSA-N FC(C(=O)OCC)(C1=NC=C(C=C1)CO)F Chemical compound FC(C(=O)OCC)(C1=NC=C(C=C1)CO)F HIAGFGLYKBPSCG-UHFFFAOYSA-N 0.000 description 2
- TVSWFSYWXDYXQG-UHFFFAOYSA-N FC(C(=O)OCC)(C1=NC=C(N=C1)C)F Chemical compound FC(C(=O)OCC)(C1=NC=C(N=C1)C)F TVSWFSYWXDYXQG-UHFFFAOYSA-N 0.000 description 2
- ZHJZRYMHYLFQOX-UHFFFAOYSA-N FC(C1=CC=C(C=C1)C(C(=O)OCC)(F)F)F Chemical compound FC(C1=CC=C(C=C1)C(C(=O)OCC)(F)F)F ZHJZRYMHYLFQOX-UHFFFAOYSA-N 0.000 description 2
- LENXYEGXEFGWDZ-UHFFFAOYSA-N FC(C=1C=CC(=NC=1)C(CO)(F)F)F Chemical compound FC(C=1C=CC(=NC=1)C(CO)(F)F)F LENXYEGXEFGWDZ-UHFFFAOYSA-N 0.000 description 2
- BXROVMPPCWIEMF-UHFFFAOYSA-N FC(CN1CCC(CC1)N(C=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)C)(C1=NC=C(C=C1)C)F Chemical compound FC(CN1CCC(CC1)N(C=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)C)(C1=NC=C(C=C1)C)F BXROVMPPCWIEMF-UHFFFAOYSA-N 0.000 description 2
- XABDUKQIRGURSX-UHFFFAOYSA-N FC(CN1CCC(CC1)N)(C1=CC=C(C=C1)F)F Chemical compound FC(CN1CCC(CC1)N)(C1=CC=C(C=C1)F)F XABDUKQIRGURSX-UHFFFAOYSA-N 0.000 description 2
- DYFXQUQMRDWINA-UHFFFAOYSA-N FC(CN1CCC(CC1)NC(OC(C)(C)C)=O)(C1=CC=C(C=C1)C(F)(F)F)F Chemical compound FC(CN1CCC(CC1)NC(OC(C)(C)C)=O)(C1=CC=C(C=C1)C(F)(F)F)F DYFXQUQMRDWINA-UHFFFAOYSA-N 0.000 description 2
- SPLATYAOMKKRGZ-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)(C1=NC=C(C=C1)CF)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)(C1=NC=C(C=C1)CF)F SPLATYAOMKKRGZ-UHFFFAOYSA-N 0.000 description 2
- MXVBNBATOXCGGR-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)(C1=NC=C(C=C1)OC(F)(F)F)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)(C1=NC=C(C=C1)OC(F)(F)F)F MXVBNBATOXCGGR-UHFFFAOYSA-N 0.000 description 2
- MXGRKDRGLMCRJE-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=CC=C(C=C1)C)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=CC=C(C=C1)C)F MXGRKDRGLMCRJE-UHFFFAOYSA-N 0.000 description 2
- RYFZFQVKNZTNST-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=C(C=C1)C)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=C(C=C1)C)F RYFZFQVKNZTNST-UHFFFAOYSA-N 0.000 description 2
- JWSNFGOOEXCNJU-UHFFFAOYSA-N FC(CO)(C1=NC=C(C=C1)CF)F Chemical compound FC(CO)(C1=NC=C(C=C1)CF)F JWSNFGOOEXCNJU-UHFFFAOYSA-N 0.000 description 2
- CNZNFKVCHQLJIN-UHFFFAOYSA-N FC(CO)(C1=NC=C(C=C1)OC(F)(F)F)F Chemical compound FC(CO)(C1=NC=C(C=C1)OC(F)(F)F)F CNZNFKVCHQLJIN-UHFFFAOYSA-N 0.000 description 2
- GASCWUKBKVGJHL-UHFFFAOYSA-N FC(F)(F)C1=CC=C(C=C1)C(F)(F)COS(=O)(=O)C(F)(F)F Chemical compound FC(F)(F)C1=CC=C(C=C1)C(F)(F)COS(=O)(=O)C(F)(F)F GASCWUKBKVGJHL-UHFFFAOYSA-N 0.000 description 2
- ZXJMTYVIRYGIRY-UHFFFAOYSA-N FC(OC=1C=CC(=NC=1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)(F)F)F Chemical compound FC(OC=1C=CC(=NC=1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)(F)F)F ZXJMTYVIRYGIRY-UHFFFAOYSA-N 0.000 description 2
- NGORBADNQFPKGE-UHFFFAOYSA-N FC(OC=1C=CC(=NC=1)C(CO)(F)F)F Chemical compound FC(OC=1C=CC(=NC=1)C(CO)(F)F)F NGORBADNQFPKGE-UHFFFAOYSA-N 0.000 description 2
- RIYWRXDRPIIOFE-UHFFFAOYSA-N FC(S(=O)(=O)OCC(C1=CC=C(C=C1)C)(F)F)(F)F Chemical compound FC(S(=O)(=O)OCC(C1=CC=C(C=C1)C)(F)F)(F)F RIYWRXDRPIIOFE-UHFFFAOYSA-N 0.000 description 2
- LHJXRFHJUFKNDZ-UHFFFAOYSA-N FC(S(=O)(=O)OCC(F)(F)C1=CC=C(C=C1)Cl)(F)F Chemical compound FC(S(=O)(=O)OCC(F)(F)C1=CC=C(C=C1)Cl)(F)F LHJXRFHJUFKNDZ-UHFFFAOYSA-N 0.000 description 2
- IXUWUAZQRWOQNO-UHFFFAOYSA-N FC(S(=O)(=O)OCC(F)(F)C1=NC=C(C=C1)Cl)(F)F Chemical compound FC(S(=O)(=O)OCC(F)(F)C1=NC=C(C=C1)Cl)(F)F IXUWUAZQRWOQNO-UHFFFAOYSA-N 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 201000009010 Frontal lobe epilepsy Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 208000003078 Generalized Epilepsy Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000034308 Grand mal convulsion Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101100329196 Homo sapiens CYP2D6 gene Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010021403 Illusion Diseases 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 201000005802 Landau-Kleffner Syndrome Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 2
- 206010073211 Postural tremor Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
- 208000018452 Torsade de pointes Diseases 0.000 description 2
- 208000002363 Torsades de Pointes Diseases 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000003693 atypical antipsychotic agent Substances 0.000 description 2
- 229940127236 atypical antipsychotics Drugs 0.000 description 2
- 201000002922 basal ganglia calcification Diseases 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 208000016791 bilateral striopallidodentate calcinosis Diseases 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
- 229960003120 clonazepam Drugs 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960000632 dexamfetamine Drugs 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 208000028329 epileptic seizure Diseases 0.000 description 2
- LZPFGOHOAZXQBP-UHFFFAOYSA-N ethyl 2,2-difluoro-2-(3-fluoro-5-methylpyridin-2-yl)acetate Chemical compound FC(C(=O)OCC)(C1=NC=C(C=C1F)C)F LZPFGOHOAZXQBP-UHFFFAOYSA-N 0.000 description 2
- QTJOXVLRFWKBMD-UHFFFAOYSA-N ethyl 2,2-difluoro-2-(4-fluorophenyl)acetate Chemical compound CCOC(=O)C(F)(F)C1=CC=C(F)C=C1 QTJOXVLRFWKBMD-UHFFFAOYSA-N 0.000 description 2
- XMFLSHALHZBESY-UHFFFAOYSA-N ethyl 2,2-difluoro-2-(4-methylphenyl)acetate Chemical compound CCOC(=O)C(F)(F)C1=CC=C(C)C=C1 XMFLSHALHZBESY-UHFFFAOYSA-N 0.000 description 2
- YPWORDDMSCLNSH-UHFFFAOYSA-N ethyl 2,2-difluoro-2-(5-fluoropyridin-2-yl)acetate Chemical compound CCOC(=O)C(F)(F)C1=CC=C(F)C=N1 YPWORDDMSCLNSH-UHFFFAOYSA-N 0.000 description 2
- ZXADEANRRGOUFQ-UHFFFAOYSA-N ethyl 2,2-difluoro-2-(6-methylpyridin-3-yl)acetate Chemical compound CCOC(=O)C(F)(F)C1=CC=C(C)N=C1 ZXADEANRRGOUFQ-UHFFFAOYSA-N 0.000 description 2
- HVFAWMJUAKSUKX-UHFFFAOYSA-N ethyl 2,2-difluoro-2-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]acetate Chemical compound FC(C(=O)OCC)(C1=NC=C(C=C1F)C(F)(F)F)F HVFAWMJUAKSUKX-UHFFFAOYSA-N 0.000 description 2
- RRQFNNMHAYGZTC-UHFFFAOYSA-N ethyl 2,2-difluoro-2-[5-(trifluoromethyl)pyridin-2-yl]acetate Chemical compound CCOC(=O)C(F)(F)C1=CC=C(C(F)(F)F)C=N1 RRQFNNMHAYGZTC-UHFFFAOYSA-N 0.000 description 2
- 230000036749 excitatory postsynaptic potential Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 229960004038 fluvoxamine Drugs 0.000 description 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 229960003998 ifenprodil Drugs 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 230000001057 ionotropic effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000005518 mononeuropathy Diseases 0.000 description 2
- 230000002151 myoclonic effect Effects 0.000 description 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 229950010883 phencyclidine Drugs 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 201000005070 reflex epilepsy Diseases 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229960001534 risperidone Drugs 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 208000012672 seasonal affective disease Diseases 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 208000005809 status epilepticus Diseases 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 2
- YIYDDPSLOPWBDI-UHFFFAOYSA-N tert-butyl N-[1-[2,2-difluoro-2-(5-methylpyridin-2-yl)ethyl]piperidin-4-yl]carbamate Chemical compound N(C1CCN(CC(F)(F)C2=NC=C(C)C=C2)CC1)C(=O)OC(C)(C)C YIYDDPSLOPWBDI-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- FSHWRWRFDRMLFH-UHFFFAOYSA-N (2,2-difluoro-2-pyridin-2-ylethyl) trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OCC(F)(F)C1=CC=CC=N1 FSHWRWRFDRMLFH-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DYJIKHYBKVODAC-ZDUSSCGKSA-N (2s)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one Chemical compound C([C@H]1COC=2C=CC3=C(C=2O1)CC(N3)=O)NCC1=CC=CC=C1 DYJIKHYBKVODAC-ZDUSSCGKSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- VHNYOQKVZQVBLC-RTCGXNAVSA-N (4r,7e,9as)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 description 1
- QPPDKOIDAYZUHN-UHFFFAOYSA-N (6-bromopyridin-3-yl)methanol Chemical compound OCC1=CC=C(Br)N=C1 QPPDKOIDAYZUHN-UHFFFAOYSA-N 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- GMHKMTDVRCWUDX-LBPRGKRZSA-N (S)-Mephenytoin Chemical compound C=1C=CC=CC=1[C@]1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-LBPRGKRZSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- PXUIZULXJVRBPC-UHFFFAOYSA-N 1'-[3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl]hexahydro-2H-spiro[imidazo[1,2-a]pyridine-3,4'-piperidin]-2-one Chemical compound C12=CC(Cl)=CC=C2CCC2=CC=CC=C2N1CCCN1CCC2(C(NC3CCCCN32)=O)CC1 PXUIZULXJVRBPC-UHFFFAOYSA-N 0.000 description 1
- WNCZVTPNRILHCU-UHFFFAOYSA-N 1-[2,2-difluoro-2-[6-(trifluoromethyl)pyridin-3-yl]ethyl]piperidin-4-amine Chemical compound FC(CN1CCC(CC1)N)(C=1C=NC(=CC=1)C(F)(F)F)F WNCZVTPNRILHCU-UHFFFAOYSA-N 0.000 description 1
- GWQSENYKCGJTRI-UHFFFAOYSA-N 1-chloro-4-iodobenzene Chemical compound ClC1=CC=C(I)C=C1 GWQSENYKCGJTRI-UHFFFAOYSA-N 0.000 description 1
- KGNQDBQYEBMPFZ-UHFFFAOYSA-N 1-fluoro-4-iodobenzene Chemical compound FC1=CC=C(I)C=C1 KGNQDBQYEBMPFZ-UHFFFAOYSA-N 0.000 description 1
- UDHAWRUAECEBHC-UHFFFAOYSA-N 1-iodo-4-methylbenzene Chemical compound CC1=CC=C(I)C=C1 UDHAWRUAECEBHC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZVEPSOIADHQCFD-UHFFFAOYSA-N 2,2-difluoro-2-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]acetic acid Chemical compound OC(=O)C(F)(F)c1ncc(cc1F)C(F)(F)F ZVEPSOIADHQCFD-UHFFFAOYSA-N 0.000 description 1
- OBTFFOBSOSEMFL-UHFFFAOYSA-N 2,2-difluoro-2-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]ethanol Chemical compound FC(CO)(C1=NC=C(C=C1F)C(F)(F)F)F OBTFFOBSOSEMFL-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical compound C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 description 1
- FHBVYLMBTLPHGQ-UHFFFAOYSA-N 2-bromo-3-ethyl-5-methylpyridine Chemical compound C(C)C=1C(=NC=C(C=1)C)Br FHBVYLMBTLPHGQ-UHFFFAOYSA-N 0.000 description 1
- DNVIECHQUYQOOH-UHFFFAOYSA-N 2-bromo-3-fluoro-5-(trifluoromethyl)pyridine Chemical compound FC1=CC(C(F)(F)F)=CN=C1Br DNVIECHQUYQOOH-UHFFFAOYSA-N 0.000 description 1
- OCTPYXPSXKTDIU-UHFFFAOYSA-N 2-bromo-3-fluoro-5-methylpyridine Chemical compound CC1=CN=C(Br)C(F)=C1 OCTPYXPSXKTDIU-UHFFFAOYSA-N 0.000 description 1
- PYKSHJJKXWPSHM-UHFFFAOYSA-N 2-bromo-5-(difluoromethoxy)pyridine Chemical compound FC(F)OC1=CC=C(Br)N=C1 PYKSHJJKXWPSHM-UHFFFAOYSA-N 0.000 description 1
- RKXYQQVLVNEAFB-UHFFFAOYSA-N 2-bromo-5-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)N=C1 RKXYQQVLVNEAFB-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 1
- QCYHTXABVWADTN-UHFFFAOYSA-N 3-(1,1,2,3,3,3-hexafluoropropylsulfanyl)-4-hydroxy-6-methylpyran-2-one Chemical compound CC1=CC(O)=C(SC(F)(F)C(F)C(F)(F)F)C(=O)O1 QCYHTXABVWADTN-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GUJRSXAPGDDABA-NSHDSACASA-N 3-bromo-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2,6-dimethoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC GUJRSXAPGDDABA-NSHDSACASA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- GJSVCUHWEJFFMO-UHFFFAOYSA-N 3-iodo-2-methylpyridine Chemical compound CC1=NC=CC=C1I GJSVCUHWEJFFMO-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
- NIEBHDXUIJSHSL-UHFFFAOYSA-N 4-iodobenzaldehyde Chemical compound IC1=CC=C(C=O)C=C1 NIEBHDXUIJSHSL-UHFFFAOYSA-N 0.000 description 1
- CXWLXKZIXLOBCC-UHFFFAOYSA-N 5-chloro-2-iodopyridine Chemical compound ClC1=CC=C(I)N=C1 CXWLXKZIXLOBCC-UHFFFAOYSA-N 0.000 description 1
- FPUPPVDVOFJSEP-UHFFFAOYSA-N 5-chloro-3-fluoropyridin-2-amine Chemical compound NC1=NC=C(Cl)C=C1F FPUPPVDVOFJSEP-UHFFFAOYSA-N 0.000 description 1
- YJTXQLYMECWULH-UHFFFAOYSA-N 5-fluoropyridin-2-amine Chemical compound NC1=CC=C(F)C=N1 YJTXQLYMECWULH-UHFFFAOYSA-N 0.000 description 1
- IBOZOWZSXZNIHI-UHFFFAOYSA-N 6-(trifluoromethyl)pyridin-3-amine Chemical compound NC1=CC=C(C(F)(F)F)N=C1 IBOZOWZSXZNIHI-UHFFFAOYSA-N 0.000 description 1
- PVUKGNBRJFTFNJ-UHFFFAOYSA-N 6-bromopyridine-3-carbaldehyde Chemical compound BrC1=CC=C(C=O)C=N1 PVUKGNBRJFTFNJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- YVPUUUDAZYFFQT-UHFFFAOYSA-N 7-(4-methylpiperazin-1-yl)-3h-1,3-benzoxazol-2-one Chemical compound C1CN(C)CCN1C1=CC=CC2=C1OC(=O)N2 YVPUUUDAZYFFQT-UHFFFAOYSA-N 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003628 Atonic seizures Diseases 0.000 description 1
- 208000035183 Benign hereditary chorea Diseases 0.000 description 1
- 206010070530 Benign rolandic epilepsy Diseases 0.000 description 1
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 description 1
- XVGOZDAJGBALKS-UHFFFAOYSA-N Blonanserin Chemical compound C1CN(CC)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(CCCCCC2)C2=N1 XVGOZDAJGBALKS-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- HZUZPAHCTMWRMS-UHFFFAOYSA-N C(C)C=1C(=NC=C(N=1)C)I Chemical compound C(C)C=1C(=NC=C(N=1)C)I HZUZPAHCTMWRMS-UHFFFAOYSA-N 0.000 description 1
- 102100029962 CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Human genes 0.000 description 1
- JVTYWYSPNRFDAD-UHFFFAOYSA-N CS(O)(=O)=O.FC(F)(F)c1ccc(cc1)C(F)(F)CN1CCC(CC1)Nc1ncnc2[nH]ccc12 Chemical compound CS(O)(=O)=O.FC(F)(F)c1ccc(cc1)C(F)(F)CN1CCC(CC1)Nc1ncnc2[nH]ccc12 JVTYWYSPNRFDAD-UHFFFAOYSA-N 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102100031265 Chromodomain-helicase-DNA-binding protein 2 Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- TZYBBXJSLBTITO-UHFFFAOYSA-N Cl.CN(C1CCN(CC(F)(F)c2ccc(C)cn2)CC1)c1ncnc2[nH]ccc12 Chemical compound Cl.CN(C1CCN(CC(F)(F)c2ccc(C)cn2)CC1)c1ncnc2[nH]ccc12 TZYBBXJSLBTITO-UHFFFAOYSA-N 0.000 description 1
- OLEGVSOVHRDKET-UHFFFAOYSA-N Cl.Cc1ccc(cc1)C(F)C(F)N1CCC(CC1)Nc1ncnc2[nH]ccc12 Chemical compound Cl.Cc1ccc(cc1)C(F)C(F)N1CCC(CC1)Nc1ncnc2[nH]ccc12 OLEGVSOVHRDKET-UHFFFAOYSA-N 0.000 description 1
- DUMSRZGBFJRJCV-UHFFFAOYSA-N Cl.Cc1ccc(cn1)C(F)(F)C(=O)N1CCC(N)CC1 Chemical compound Cl.Cc1ccc(cn1)C(F)(F)C(=O)N1CCC(N)CC1 DUMSRZGBFJRJCV-UHFFFAOYSA-N 0.000 description 1
- ZXIBUZZQHWOBLZ-UHFFFAOYSA-N Cl.FC(F)(CN1CCC(CC1)Nc1ncnc2[nH]ccc12)c1ccc(Cl)cc1 Chemical compound Cl.FC(F)(CN1CCC(CC1)Nc1ncnc2[nH]ccc12)c1ccc(Cl)cc1 ZXIBUZZQHWOBLZ-UHFFFAOYSA-N 0.000 description 1
- YPBJSDYMTHLHFQ-UHFFFAOYSA-N Cl.FC(F)(CN1CCC(CC1)Nc1ncnc2[nH]ccc12)c1ccccn1 Chemical compound Cl.FC(F)(CN1CCC(CC1)Nc1ncnc2[nH]ccc12)c1ccccn1 YPBJSDYMTHLHFQ-UHFFFAOYSA-N 0.000 description 1
- CXOQIBUOLPQCJO-UHFFFAOYSA-N Cl.FC(F)(F)Oc1ccc(nc1)C(F)(F)CN1CCC(CC1)Nc1ncnc2[nH]ccc12 Chemical compound Cl.FC(F)(F)Oc1ccc(nc1)C(F)(F)CN1CCC(CC1)Nc1ncnc2[nH]ccc12 CXOQIBUOLPQCJO-UHFFFAOYSA-N 0.000 description 1
- TVTXFZBQBJOAFJ-UHFFFAOYSA-N Cl.FC(F)c1ccc(nc1)C(F)(F)CN1CCC(CC1)Nc1ncnc2[nH]ccc12 Chemical compound Cl.FC(F)c1ccc(nc1)C(F)(F)CN1CCC(CC1)Nc1ncnc2[nH]ccc12 TVTXFZBQBJOAFJ-UHFFFAOYSA-N 0.000 description 1
- UKVNYBKMFNVZSU-UHFFFAOYSA-N Cl.FCc1ccc(nc1)C(F)(F)CN1CCC(CC1)Nc1ncnc2[nH]ccc12 Chemical compound Cl.FCc1ccc(nc1)C(F)(F)CN1CCC(CC1)Nc1ncnc2[nH]ccc12 UKVNYBKMFNVZSU-UHFFFAOYSA-N 0.000 description 1
- OVSKKSKHLPZMCJ-UHFFFAOYSA-N Cl.Fc1cc(cnc1C(F)(F)CN1CCC(CC1)Nc1ncnc2[nH]ccc12)C(F)(F)F Chemical compound Cl.Fc1cc(cnc1C(F)(F)CN1CCC(CC1)Nc1ncnc2[nH]ccc12)C(F)(F)F OVSKKSKHLPZMCJ-UHFFFAOYSA-N 0.000 description 1
- OAWWVOSHDXIRDS-UHFFFAOYSA-N ClC1=CC=C(C=C1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(F)F Chemical compound ClC1=CC=C(C=C1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(F)F OAWWVOSHDXIRDS-UHFFFAOYSA-N 0.000 description 1
- QOTIEMUIZUBYME-UHFFFAOYSA-N ClC=1C=CC(=NC=1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(F)F Chemical compound ClC=1C=CC(=NC=1)C(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(F)F QOTIEMUIZUBYME-UHFFFAOYSA-N 0.000 description 1
- KAAZGXDPUNNEFN-UHFFFAOYSA-N Clotiapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2SC2=CC=C(Cl)C=C12 KAAZGXDPUNNEFN-UHFFFAOYSA-N 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000032065 Convulsion neonatal Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010070666 Cortical dysplasia Diseases 0.000 description 1
- 102100034746 Cyclin-dependent kinase-like 5 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 229940081615 DOPA decarboxylase inhibitor Drugs 0.000 description 1
- 101000923091 Danio rerio Aristaless-related homeobox protein Proteins 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012225 Delirium tremens Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 201000007547 Dravet syndrome Diseases 0.000 description 1
- 206010052805 Drug tolerance decreased Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 description 1
- 206010071545 Early infantile epileptic encephalopathy with burst-suppression Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- GMQSZLPGPWKVEI-UHFFFAOYSA-N FC(C(=O)OCC)(C1=NC=C(C=C1)OC(F)(F)F)F Chemical compound FC(C(=O)OCC)(C1=NC=C(C=C1)OC(F)(F)F)F GMQSZLPGPWKVEI-UHFFFAOYSA-N 0.000 description 1
- RUYOWKLUAHLTAK-UHFFFAOYSA-N FC(C(F)N1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)C1=NC=C(C=C1)OC(F)(F)F Chemical compound FC(C(F)N1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)C1=NC=C(C=C1)OC(F)(F)F RUYOWKLUAHLTAK-UHFFFAOYSA-N 0.000 description 1
- LNXWQRLNEIHICL-UHFFFAOYSA-N FC(CN1CCC(CC1)N(C=1N=CC2=C(N=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)C)(C1=NC=C(C=C1)C)F Chemical compound FC(CN1CCC(CC1)N(C=1N=CC2=C(N=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)C)(C1=NC=C(C=C1)C)F LNXWQRLNEIHICL-UHFFFAOYSA-N 0.000 description 1
- MWYUFCIEBXRPHH-UHFFFAOYSA-N FC(CN1CCC(CC1)NC1=C2C(=NC=N1)N(N=C2)S(=O)(=O)C1=CC=C(C)C=C1)(C1=NC=C(C=C1F)C)F Chemical compound FC(CN1CCC(CC1)NC1=C2C(=NC=N1)N(N=C2)S(=O)(=O)C1=CC=C(C)C=C1)(C1=NC=C(C=C1F)C)F MWYUFCIEBXRPHH-UHFFFAOYSA-N 0.000 description 1
- HPSRRLVDYCZGAJ-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)(C1=NC=C(C=C1)C)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)(C1=NC=C(C=C1)C)F HPSRRLVDYCZGAJ-UHFFFAOYSA-N 0.000 description 1
- CSLAFKNTMSZKMA-UHFFFAOYSA-N FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C=1C=NC(=CC=1)C(F)(F)F)F Chemical compound FC(CN1CCC(CC1)NC=1C2=C(N=CN=1)NC=C2)(C=1C=NC(=CC=1)C(F)(F)F)F CSLAFKNTMSZKMA-UHFFFAOYSA-N 0.000 description 1
- APVNTGKHIYNBNP-UHFFFAOYSA-N FC(S(=O)(=O)OCC(F)(F)C1=NC=C(C=C1)C(F)F)(F)F Chemical compound FC(S(=O)(=O)OCC(F)(F)C1=NC=C(C=C1)C(F)F)(F)F APVNTGKHIYNBNP-UHFFFAOYSA-N 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 102100035924 Gamma-aminobutyric acid type B receptor subunit 2 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000009693 Gingival Hyperplasia Diseases 0.000 description 1
- 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 description 1
- 102100022626 Glutamate receptor ionotropic, NMDA 2D Human genes 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 102100031470 Homeobox protein ARX Human genes 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- 101000863898 Homo sapiens CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Proteins 0.000 description 1
- 101000777079 Homo sapiens Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 description 1
- 101000945692 Homo sapiens Cyclin-dependent kinase-like 5 Proteins 0.000 description 1
- 101000880945 Homo sapiens Down syndrome cell adhesion molecule Proteins 0.000 description 1
- 101001000703 Homo sapiens Gamma-aminobutyric acid type B receptor subunit 2 Proteins 0.000 description 1
- 101001125242 Homo sapiens Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 description 1
- 101000923090 Homo sapiens Homeobox protein ARX Proteins 0.000 description 1
- 101000641879 Homo sapiens Ras/Rap GTPase-activating protein SynGAP Proteins 0.000 description 1
- 101000648077 Homo sapiens Syntaxin-binding protein 1 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010071081 Idiopathic generalised epilepsy Diseases 0.000 description 1
- 208000016588 Idiopathic hypersomnia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 206010022520 Intention tremor Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000005870 Lafora disease Diseases 0.000 description 1
- 208000014161 Lafora myoclonic epilepsy Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- FWJKNZONDWOGMI-UHFFFAOYSA-N Metharbital Chemical compound CCC1(CC)C(=O)NC(=O)N(C)C1=O FWJKNZONDWOGMI-UHFFFAOYSA-N 0.000 description 1
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- LVPDXWUMXNVOKV-UHFFFAOYSA-N N-[1-(2,2-difluoro-2-pyridin-2-ylethyl)piperidin-2-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound FC(CN1C(CCCC1)NC=1C2=C(N=CN=1)NC=C2)(C1=NC=CC=C1)F LVPDXWUMXNVOKV-UHFFFAOYSA-N 0.000 description 1
- UENXXBFQUWZBHZ-UHFFFAOYSA-N N-[1-[2,2-difluoro-2-(3-fluoro-5-methylpyridin-2-yl)ethyl]piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine hydrochloride Chemical compound Cl.Cc1cnc(c(F)c1)C(F)(F)CN1CCC(CC1)Nc1ncnc2[nH]ncc12 UENXXBFQUWZBHZ-UHFFFAOYSA-N 0.000 description 1
- PXMPXYWOQWZHDZ-UHFFFAOYSA-N N-[1-[2,2-difluoro-2-[5-(trifluoromethyl)pyridin-2-yl]ethyl]piperidin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride Chemical compound Cl.FC(F)(F)c1ccc(nc1)C(F)(F)CN1CCC(CC1)Nc1ncnc2[nH]ccc12 PXMPXYWOQWZHDZ-UHFFFAOYSA-N 0.000 description 1
- SRWQAOQEGCZOFQ-UHFFFAOYSA-N N-[1-[2,2-difluoro-2-[6-(trifluoromethyl)pyridin-3-yl]ethyl]piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound FC(CN1CCC(CC1)NC1=C2C(=NC=N1)NN=C2)(C=1C=NC(=CC=1)C(F)(F)F)F SRWQAOQEGCZOFQ-UHFFFAOYSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 108091008644 NR2D Proteins 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- VQASKUSHBVDKGU-UHFFFAOYSA-N Paramethadione Chemical compound CCC1(C)OC(=O)N(C)C1=O VQASKUSHBVDKGU-UHFFFAOYSA-N 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 206010034759 Petit mal epilepsy Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- XPFRXWCVYUEORT-UHFFFAOYSA-N Phenacemide Chemical compound NC(=O)NC(=O)CC1=CC=CC=C1 XPFRXWCVYUEORT-UHFFFAOYSA-N 0.000 description 1
- WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000004914 RYR3 Human genes 0.000 description 1
- 108060007242 RYR3 Proteins 0.000 description 1
- 102100033428 Ras/Rap GTPase-activating protein SynGAP Human genes 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000004974 Rolandic Epilepsy Diseases 0.000 description 1
- 238000000297 Sandmeyer reaction Methods 0.000 description 1
- 101100439661 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr4 gene Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 206010067672 Spasmodic dysphonia Diseases 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
- 208000011962 Substance-induced mood disease Diseases 0.000 description 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 102100025293 Syntaxin-binding protein 1 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
- 206010050467 Tongue biting Diseases 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000003728 Vulvodynia Diseases 0.000 description 1
- 206010069055 Vulvovaginal pain Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 208000013142 Writer cramp Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- VLPKTDJHGRLLRW-UHFFFAOYSA-N [2-(5-chloro-3-fluoropyridin-2-yl)-2,2-difluoroethyl] trifluoromethanesulfonate Chemical compound FC(S(=O)(=O)OCC(F)(F)C1=NC=C(C=C1F)Cl)(F)F VLPKTDJHGRLLRW-UHFFFAOYSA-N 0.000 description 1
- PCBOWMZAEDDKNH-HOTGVXAUSA-N [4-(trifluoromethoxy)phenyl]methyl (3as,6as)-2-(3-fluoro-4-sulfamoylbenzoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1=C(F)C(S(=O)(=O)N)=CC=C1C(=O)N1C[C@H]2CN(C(=O)OCC=3C=CC(OC(F)(F)F)=CC=3)C[C@@H]2C1 PCBOWMZAEDDKNH-HOTGVXAUSA-N 0.000 description 1
- DDSZWBCJXDRQDU-UHFFFAOYSA-N [N].C1CCNCC1 Chemical group [N].C1CCNCC1 DDSZWBCJXDRQDU-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- ZVDDJPSHRNMSKV-UHFFFAOYSA-N acetaldehyde;hydrochloride Chemical compound Cl.CC=O ZVDDJPSHRNMSKV-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940047812 adderall Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 208000006246 alcohol withdrawal delirium Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940125516 allosteric modulator Drugs 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- JBBIRCXHVMJESY-UHFFFAOYSA-N amino piperidine-1-carboxylate Chemical compound NOC(=O)N1CCCCC1 JBBIRCXHVMJESY-UHFFFAOYSA-N 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940124433 antimigraine drug Drugs 0.000 description 1
- 229950001748 aplindore Drugs 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005245 asenapine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- IUKQLMGVFMDQDP-UHFFFAOYSA-N azane;piperidine Chemical compound N.C1CCNCC1 IUKQLMGVFMDQDP-UHFFFAOYSA-N 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 201000008916 benign epilepsy with centrotemporal spikes Diseases 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229950009087 bifeprunox Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 229950002871 blonanserin Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000033205 childhood epilepsy with centrotemporal spikes Diseases 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 229950006515 ciladopa Drugs 0.000 description 1
- SGEKLKJQLHJVDK-LJQANCHMSA-N ciladopa Chemical compound C1=C(OC)C(OC)=CC=C1[C@H](O)CN1CCN(C=2C(C=CC=CC=2)=O)CC1 SGEKLKJQLHJVDK-LJQANCHMSA-N 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229960001403 clobazam Drugs 0.000 description 1
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960004362 clorazepate Drugs 0.000 description 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 description 1
- 229960003864 clotiapine Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 description 1
- 229960005217 dapoxetine Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
- DUGOZIWVEXMGBE-CHWSQXEVSA-N dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 description 1
- 229960001042 dexmethylphenidate Drugs 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 description 1
- 229960002032 dihydroergocryptine Drugs 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- XQGPKZUNMMFTAL-UHFFFAOYSA-L dipotassium;hydrogen phosphate;trihydrate Chemical compound O.O.O.[K+].[K+].OP([O-])([O-])=O XQGPKZUNMMFTAL-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000000632 dystonic effect Effects 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 229950007832 encenicline Drugs 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- XCGSFFUVFURLIX-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1 XCGSFFUVFURLIX-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960003533 ethotoin Drugs 0.000 description 1
- SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 description 1
- HGWXXIZVRRTDKT-UHFFFAOYSA-N ethyl 2,2-difluoro-2-iodoacetate Chemical compound CCOC(=O)C(F)(F)I HGWXXIZVRRTDKT-UHFFFAOYSA-N 0.000 description 1
- AHLZMMPDDACOQX-UHFFFAOYSA-N ethyl 2,2-difluoro-2-pyridin-2-ylacetate Chemical compound CCOC(=O)C(F)(F)C1=CC=CC=N1 AHLZMMPDDACOQX-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229960003472 felbamate Drugs 0.000 description 1
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 239000012025 fluorinating agent Substances 0.000 description 1
- 229960002419 flupentixol Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 201000002904 focal dystonia Diseases 0.000 description 1
- 201000002865 focal hand dystonia Diseases 0.000 description 1
- 229960000693 fosphenytoin Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 description 1
- 229960003162 iloperidone Drugs 0.000 description 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229950002473 indalpine Drugs 0.000 description 1
- SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000028756 lack of coordination Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960001451 lisdexamfetamine Drugs 0.000 description 1
- VOBHXZCDAVEXEY-JSGCOSHPSA-N lisdexamfetamine Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 VOBHXZCDAVEXEY-JSGCOSHPSA-N 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 229960000906 mephenytoin Drugs 0.000 description 1
- GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 description 1
- ALARQZQTBTVLJV-UHFFFAOYSA-N mephobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 description 1
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
- 229960000300 mesoridazine Drugs 0.000 description 1
- 229960003729 mesuximide Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960002057 metharbital Drugs 0.000 description 1
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
- 229940042053 methotrimeprazine Drugs 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960001703 methylphenobarbital Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960004938 molindone Drugs 0.000 description 1
- 229940126403 monoamine reuptake inhibitor Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229960003894 mosapramine Drugs 0.000 description 1
- SSRDSYXGYPJKRR-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC(C=CC=C2Cl)=C2S1 SSRDSYXGYPJKRR-ZDUSSCGKSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000007431 neuroacanthocytosis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000037860 neuroleptic-induced Akathisia Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000017511 neuron migration Effects 0.000 description 1
- 230000007604 neuronal communication Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000000181 nicotinic agonist Substances 0.000 description 1
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 201000002851 oromandibular dystonia Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001057 paliperidone Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960003274 paramethadione Drugs 0.000 description 1
- 229950010798 pardoprunox Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229950004193 perospirone Drugs 0.000 description 1
- GTAIPSDXDDTGBZ-OYRHEFFESA-N perospirone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCN3C(=O)[C@@H]4CCCC[C@@H]4C3=O)=NSCC2=C1 GTAIPSDXDDTGBZ-OYRHEFFESA-N 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003396 phenacemide Drugs 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229960004227 phensuximide Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 201000003040 photosensitive epilepsy Diseases 0.000 description 1
- RKEWSXXUOLRFBX-UHFFFAOYSA-N pimavanserin Chemical compound C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1 RKEWSXXUOLRFBX-UHFFFAOYSA-N 0.000 description 1
- 229960003300 pimavanserin Drugs 0.000 description 1
- KCYQSFOCCXSZQY-UHFFFAOYSA-N piperidin-4-yl carbamate Chemical compound NC(=O)OC1CCNCC1 KCYQSFOCCXSZQY-UHFFFAOYSA-N 0.000 description 1
- KBOGICFUPOMDKS-UHFFFAOYSA-N piperidin-4-ylcarbamic acid Chemical compound OC(=O)NC1CCNCC1 KBOGICFUPOMDKS-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229960004310 piribedil Drugs 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 230000036278 prepulse Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960003448 remoxipride Drugs 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229960003179 rotigotine Drugs 0.000 description 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000009991 second messenger activation Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000004003 serotonin 1D agonist Substances 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 229960000652 sertindole Drugs 0.000 description 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 201000002849 spasmodic dystonia Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 201000006152 substance dependence Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- BTYHAYZTYOWFQL-UHFFFAOYSA-N tert-butyl 1-aminopiperidine-4-carboxylate Chemical class CC(C)(C)OC(=O)C1CCN(N)CC1 BTYHAYZTYOWFQL-UHFFFAOYSA-N 0.000 description 1
- NQXAGAQVXCUUFQ-UHFFFAOYSA-N tert-butyl N-[1-[2,2-difluoro-2-[5-(trifluoromethyl)pyridin-2-yl]ethyl]piperidin-4-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CCN(CC1)CC(C1=NC=C(C=C1)C(F)(F)F)(F)F)=O NQXAGAQVXCUUFQ-UHFFFAOYSA-N 0.000 description 1
- WVSXDOFORUHIGO-UHFFFAOYSA-N tert-butyl N-[1-[2,2-difluoro-2-[6-(trifluoromethyl)pyridin-3-yl]ethyl]piperidin-4-yl]carbamate Chemical compound FC(CN1CCC(CC1)NC(OC(C)(C)C)=O)(C=1C=NC(=CC=1)C(F)(F)F)F WVSXDOFORUHIGO-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 108091008646 testicular receptors Proteins 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 1
- 229960001918 tiagabine Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960005013 tiotixene Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229950005135 traxoprodil Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 229960004453 trimethadione Drugs 0.000 description 1
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- NPTIPEQJIDTVKR-STQMWFEESA-N vabicaserin Chemical compound C1CNCC2=CC=CC3=C2N1C[C@@H]1CCC[C@@H]13 NPTIPEQJIDTVKR-STQMWFEESA-N 0.000 description 1
- 229950009968 vabicaserin Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 229960003740 vilazodone Drugs 0.000 description 1
- SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229960002791 zimeldine Drugs 0.000 description 1
- OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- 229960004496 zotepine Drugs 0.000 description 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 1
- 229960004141 zuclopenthixol Drugs 0.000 description 1
- 229940124648 γ-Secretase Modulator Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050692P | 2014-09-15 | 2014-09-15 | |
| PCT/US2015/050267 WO2016044323A1 (en) | 2014-09-15 | 2015-09-15 | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3194403T3 true DK3194403T3 (en) | 2019-04-15 |
Family
ID=54293326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15779059.3T DK3194403T3 (en) | 2014-09-15 | 2015-09-15 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9567341B2 (enExample) |
| EP (1) | EP3194403B1 (enExample) |
| JP (1) | JP6612331B2 (enExample) |
| KR (1) | KR102569031B1 (enExample) |
| CN (1) | CN106715435B (enExample) |
| AU (1) | AU2015317886A1 (enExample) |
| CA (1) | CA2957898C (enExample) |
| DK (1) | DK3194403T3 (enExample) |
| ES (1) | ES2723436T3 (enExample) |
| IL (1) | IL251027A0 (enExample) |
| MX (1) | MX2017002775A (enExample) |
| RU (1) | RU2017107558A (enExample) |
| SG (1) | SG11201701853YA (enExample) |
| WO (1) | WO2016044323A1 (enExample) |
| ZA (1) | ZA201701069B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201609741A (zh) * | 2014-06-04 | 2016-03-16 | 盧郡控股（開曼）有限公司 | 作為ｎｒ２ｂ ｎｍｄａ受體拮抗劑之二氟乙基吡啶衍生物 |
| RU2017107558A (ru) | 2014-09-15 | 2018-10-18 | Руджен Холдингс (Кайман) Лимитед | Производные пирролопиримидина в качестве антагонистов nmda-рецептора nr2b |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| KR102613179B1 (ko) | 2015-06-01 | 2023-12-14 | 뤼겐 홀딩스 (케이맨) 리미티드 | Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물 |
| US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| WO2019110703A1 (en) * | 2017-12-08 | 2019-06-13 | Boehringer Ingelheim International Gmbh | Imidazopyridine derivatives and the use thereof as medicament |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| CN117185897A (zh) * | 2023-08-31 | 2023-12-08 | 上海泰坦科技股份有限公司 | 一种二氟甲基卤苯的合成方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0843661T3 (da) | 1995-08-11 | 2002-07-22 | Pfizer | (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethansulfonat-trihydrat |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| PL364625A1 (en) | 2001-02-23 | 2004-12-13 | Merck & Co, Inc. | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
| US7592360B2 (en) | 2003-06-04 | 2009-09-22 | Merck & Co., Inc. | 3-fluoro-piperidines as NMDA/NR2B antagonists |
| SI1648882T1 (sl) | 2003-06-04 | 2009-02-28 | Merck & Co Inc | 3-fluoro-piperidini kot nmda/nr2b antagonisti |
| DE602004004278T2 (de) | 2003-08-15 | 2007-10-31 | Merck & Co, Inc. | 4-cycloalkylaminopyrazolopyrimidin als nmda/nr2b-antagonisten |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| CN1993363A (zh) | 2004-08-03 | 2007-07-04 | 默克公司 | 1,3－二取代的杂芳基nmda/nr2b拮抗剂 |
| CA2591738A1 (en) | 2004-12-22 | 2006-06-29 | Merck & Co., Inc. | Process for making substituted piperidines |
| EP1874318A2 (en) * | 2005-04-19 | 2008-01-09 | Merck & Co., Inc. | N-alkyl-azacycloalkyl nmda/nr2b antagonists |
| EP1913000B1 (en) | 2005-07-29 | 2012-01-11 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis |
| WO2007061868A2 (en) | 2005-11-17 | 2007-05-31 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| BRPI0720986A2 (pt) | 2006-12-27 | 2014-03-11 | Sanofi Aventis | Derivados de isoquinolina e isoquinolinona substituídos |
| WO2010015637A1 (en) | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
| EP2519241A2 (en) | 2009-12-28 | 2012-11-07 | Afraxis, Inc. | Methods for treating autism |
| AU2011239966B2 (en) | 2010-04-16 | 2014-05-08 | Ac Immune S.A. | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| EP2580213A4 (en) | 2010-06-09 | 2013-12-25 | Afraxis Holdings Inc | 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS |
| US20130225575A1 (en) | 2010-06-16 | 2013-08-29 | Afraxis, Inc. | Methods for treating neurological conditions |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| EP2683716A1 (en) | 2011-03-11 | 2014-01-15 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| JP6007417B2 (ja) | 2011-05-31 | 2016-10-12 | レセプトス エルエルシー | 新規ｇｌｐ−１受容体安定剤および調節剤 |
| KR20140146217A (ko) | 2012-04-20 | 2014-12-24 | 유씨비 파마, 에스.에이. | 파킨슨병을 치료하는 방법 |
| JP2016506962A (ja) | 2013-01-29 | 2016-03-07 | ノーレックス, インコーポレイテッドNaurex, Inc. | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| KR20170013890A (ko) | 2014-05-06 | 2017-02-07 | 노쓰웨스턴유니버시티 | Nmdar 조절 화합물의 조합물 |
| TW201609741A (zh) | 2014-06-04 | 2016-03-16 | 盧郡控股（開曼）有限公司 | 作為ｎｒ２ｂ ｎｍｄａ受體拮抗劑之二氟乙基吡啶衍生物 |
| RU2017107558A (ru) | 2014-09-15 | 2018-10-18 | Руджен Холдингс (Кайман) Лимитед | Производные пирролопиримидина в качестве антагонистов nmda-рецептора nr2b |
| WO2016049048A1 (en) | 2014-09-22 | 2016-03-31 | Rugen Holdings (Cayman) Limited | Treatment of anxiety disorders and autism spectrum disorders |
| WO2016100349A2 (en) | 2014-12-16 | 2016-06-23 | Rugen Holdings (Cayman) Limited | Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| KR102613179B1 (ko) | 2015-06-01 | 2023-12-14 | 뤼겐 홀딩스 (케이맨) 리미티드 | Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물 |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
-
2015
- 2015-09-15 RU RU2017107558A patent/RU2017107558A/ru not_active Application Discontinuation
- 2015-09-15 KR KR1020177010056A patent/KR102569031B1/ko active Active
- 2015-09-15 ES ES15779059T patent/ES2723436T3/es active Active
- 2015-09-15 WO PCT/US2015/050267 patent/WO2016044323A1/en not_active Ceased
- 2015-09-15 EP EP15779059.3A patent/EP3194403B1/en active Active
- 2015-09-15 SG SG11201701853YA patent/SG11201701853YA/en unknown
- 2015-09-15 AU AU2015317886A patent/AU2015317886A1/en not_active Abandoned
- 2015-09-15 CA CA2957898A patent/CA2957898C/en active Active
- 2015-09-15 JP JP2017514306A patent/JP6612331B2/ja active Active
- 2015-09-15 MX MX2017002775A patent/MX2017002775A/es unknown
- 2015-09-15 DK DK15779059.3T patent/DK3194403T3/en active
- 2015-09-15 CN CN201580049617.5A patent/CN106715435B/zh active Active
- 2015-09-15 US US14/855,010 patent/US9567341B2/en active Active
-
2017
- 2017-02-09 US US15/428,321 patent/US9968610B2/en active Active
- 2017-02-13 ZA ZA2017/01069A patent/ZA201701069B/en unknown
- 2017-03-08 IL IL251027A patent/IL251027A0/en unknown
-
2018
- 2018-04-24 US US15/961,553 patent/US10420768B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL251027A0 (en) | 2017-04-30 |
| ZA201701069B (en) | 2019-07-31 |
| CA2957898C (en) | 2023-02-21 |
| RU2017107558A (ru) | 2018-10-18 |
| EP3194403A1 (en) | 2017-07-26 |
| AU2015317886A1 (en) | 2017-03-09 |
| US20180303834A1 (en) | 2018-10-25 |
| MX2017002775A (es) | 2017-08-10 |
| US20160075713A1 (en) | 2016-03-17 |
| KR102569031B1 (ko) | 2023-08-22 |
| KR20170049602A (ko) | 2017-05-10 |
| RU2017107558A3 (enExample) | 2019-03-18 |
| SG11201701853YA (en) | 2017-04-27 |
| US10420768B2 (en) | 2019-09-24 |
| US9968610B2 (en) | 2018-05-15 |
| CN106715435B (zh) | 2019-10-01 |
| CA2957898A1 (en) | 2016-03-24 |
| EP3194403B1 (en) | 2019-02-06 |
| ES2723436T3 (es) | 2019-08-27 |
| US20170209449A1 (en) | 2017-07-27 |
| JP6612331B2 (ja) | 2019-11-27 |
| JP2017526724A (ja) | 2017-09-14 |
| WO2016044323A1 (en) | 2016-03-24 |
| BR112017004868A2 (pt) | 2017-12-12 |
| CN106715435A (zh) | 2017-05-24 |
| US9567341B2 (en) | 2017-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3194403T3 (en) | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | |
| EP3152213B1 (en) | Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists | |
| AU2016270677B2 (en) | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | |
| WO2016100349A2 (en) | Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists | |
| WO2016126869A1 (en) | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists | |
| BR112017004868B1 (pt) | Derivados de pirrolopirimidina como antagonistas do receptor nmda nr2b e composição farmacêutica que os compreende | |
| HK1241366A1 (en) | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists | |
| HK1241366B (en) | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists | |
| HK1253023B (en) | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |